{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T19:17:22Z","timestamp":1779218242271,"version":"3.51.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Drug delivery systems (DDS) offer a promising strategy to enhance the therapeutic index of chemotherapeutic agents in colon cancer by improving tumor targeting, circulation time, and controlled drug release. Despite extensive preclinical research, a quantitative synthesis evaluating the efficacy of DDS and the influence of design parameters remains lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review and meta-analysis of preclinical in vivo studies assessing DDS-based chemotherapy in murine models of colon cancer. A comprehensive search of PubMed, EMBASE, Scopus, Google Scholar, Cochrane CENTRAL, and ClinicalTrials.gov was performed through October 15, 2025. Outcomes included tumor growth inhibition, with subgroup analyses examining the effects of DDS platform, chemotherapeutic agent, targeting strategy, ligand type, and route of administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty-three studies comprising 25 experiments and 539 animals were included. Overall, DDS-based therapies significantly reduced tumor growth compared with controls ((WMD: \u2212\u2009557.7; 95% CI: \u2212\u2009716.8 to \u2212\u2009398.5; I\u00b2=88%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and free-drug administration ((WMD: \u2212\u2009276.3; 95% CI: \u2212\u2009367.6 to \u2212\u2009185.1; I\u00b2=78%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Both targeted and non-targeted DDS significantly reduced tumor growth compared with free drug treatment, while targeted DDS showed significantly greater efficacy than non-targeted systems (WMD: \u2212\u2009240.3; 95% CI: \u2212\u2009399.4 to \u2212\u200981.25; I\u00b2=59%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003). Although no statistically significant differences were observed between DDS platforms or chemotherapeutic agent subgroups, micelle-based systems and DDS formulations incorporating SN-38 or doxorubicin tended to show greater tumor growth reduction. Intravenous administration demonstrated significantly greater efficacy than intraperitoneal delivery, while hyaluronic acid- and aptamer-based targeting strategies achieved the largest tumor growth inhibition. Risk-of-bias assessment indicated moderate methodological quality, with variability in reporting of randomization, blinding, and sample size calculations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>DDS-based chemotherapy consistently improves antitumor efficacy in preclinical colon cancer models, with targeting strategy, platform type, chemotherapeutic agent, and administration route influencing outcomes. These findings support the rational design of DDS platforms and underscore their translational potential. Rigorous preclinical study design and standardized reporting of efficacy and safety are essential to facilitate clinical translation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s43046-026-00365-8","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:26:07Z","timestamp":1779211567000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preclinical efficacy of drug delivery systems in colon cancer therapy: a systematic review and meta-analysis of in vivo animal studies"],"prefix":"10.1186","volume":"38","author":[{"given":"Rozafa","family":"Koliqi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arlinda","family":"Daka Grapci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Y. Henein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agata","family":"Bielecka-Dabrowa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibadete","family":"Byty\u00e7i","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"issue":"1","key":"365_CR1","first-page":"7","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: Cancer J Clin. 2019;69(1):7\u201334.","journal-title":"CA: Cancer J Clin"},{"key":"365_CR2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3322\/caac.21601","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Sauer AG, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2020. Cancer J Clin. 2020;70:145\u201364.","journal-title":"Cancer J Clin"},{"issue":"4","key":"365_CR3","doi-asserted-by":"publisher","first-page":"775","DOI":"10.2174\/0122117385307311240506104035","volume":"13","author":"R Koliqi","year":"2025","unstructured":"Koliqi R, Uskokovi\u0107 V, Breznica Selmani P, Daka Grapci A, Mahapatra C. Polymeric nanoparticles for wound healing. Pharm Nanatechnol. 2025;13(4):775\u201393.","journal-title":"Pharm Nanatechnol"},{"issue":"3","key":"365_CR4","doi-asserted-by":"publisher","first-page":"zrae038","DOI":"10.1093\/bjsopen\/zrae038","volume":"8","author":"HG Smith","year":"2024","unstructured":"Smith HG, Nilsson PJ, Shogan BD, Harji D, Gambacorta MA, Romano A, Brandl A, Qvortrup C. Neoadjuvant treatment of colorectal cancer: comprehensive review. BJS Open. 2024;8(3):zrae038.","journal-title":"BJS Open"},{"key":"365_CR5","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s12957-020-02103-3","volume":"18","author":"X Deng","year":"2020","unstructured":"Deng X, Hou J, Deng Q, Zhong Z. Predictive value of clinical toxicities of chemotherapy with fluoropyrimidines and oxaliplatin in colorectal cancer by DPYD and GSTP1 gene polymorphisms. World J Surg Oncol. 2020;18:304.","journal-title":"World J Surg Oncol"},{"key":"365_CR6","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1186\/s12885-020-06904-3","volume":"20","author":"R Negarandeh","year":"2020","unstructured":"Negarandeh R, Salehifar E, Saghafi F, et al. Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients. BMC Cancer. 2020;20:560.","journal-title":"BMC Cancer"},{"issue":"12","key":"365_CR7","doi-asserted-by":"publisher","first-page":"e034508","DOI":"10.1136\/bmjopen-2019-034508","volume":"9","author":"NL de Boer","year":"2019","unstructured":"de Boer NL, Brandt-Kerkhof ARM, Madsen EVE, Diepeveen M, van Meerten E, van Eerden RAG, et al. Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin: protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial. BMJ Open. 2019;9(12):e034508.","journal-title":"BMJ Open"},{"key":"365_CR8","doi-asserted-by":"publisher","first-page":"122899","DOI":"10.1016\/j.lfs.2024.122899","volume":"352","author":"AN Al-Thani","year":"2024","unstructured":"Al-Thani AN, Jan AG, Abbas M, Geetha M, Sadasivuni KK. Nanoparticles in cancer theragnostic and drug delivery: A comprehensive review. Life Sci. 2024;352:122899.","journal-title":"Life Sci"},{"key":"365_CR9","doi-asserted-by":"crossref","unstructured":"Fang LR, Wang YH, Xiong ZZ, Wang YM. Research progress of nanomaterials in tumor-targeted drug delivery and imaging therapy. OpenNano. 2023;14:100184.","DOI":"10.1016\/j.onano.2023.100184"},{"issue":"4","key":"365_CR10","first-page":"292","volume":"108","author":"Y Gunji","year":"2013","unstructured":"Gunji Y, Seki S, Hoshino Y, et al. Intraperitoneal drug delivery in patients with peritoneal metastases: an update. J Surg Oncol. 2013;108(4):292\u20139.","journal-title":"J Surg Oncol"},{"issue":"6","key":"365_CR11","first-page":"1562","volume":"5","author":"X Ye","year":"2013","unstructured":"Ye X, Zhang Y, Liu J, et al. Peritoneal drug delivery for peritoneal metastasis: a review of recent advances and challenges. Oncol Lett. 2013;5(6):1562\u201370.","journal-title":"Oncol Lett"},{"issue":"6","key":"365_CR12","doi-asserted-by":"publisher","first-page":"e17488","DOI":"10.1016\/j.heliyon.2023.e17488","volume":"9","author":"TC Ezike","year":"2023","unstructured":"Ezike TC, Okpala US, Onoja UL, Nwike CP, Ezeako EC, Okpara OJ, Okoroafor CC, Eze SC, Kalu OL, Odoh EC, Nwadike UG, Ogbodo JO, Umeh BU, Ossai EC, Nwanguma BC. Advances in drug delivery systems, challenges and future directions. Heliyon. 2023;9(6):e17488.","journal-title":"Heliyon"},{"issue":"2","key":"365_CR13","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.bbcan.2019.04.006","volume":"1871","author":"PY Liyanage","year":"2019","unstructured":"Liyanage PY, Hettiarachchi SD, Zhou Y, Ouhtit A, Seven ES, Oztan CY, Celik E, Leblanc RM. Nanoparticle-mediated targeted drug delivery for breast cancer treatment. Biochim Biophys Acta Rev Cancer. 2019;1871(2):419\u201333.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"1","key":"365_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1021\/acsomega.2c04078","volume":"8","author":"A Sharma","year":"2022","unstructured":"Sharma A, Shambhwani D, Pandey S, Singh J, Lalhlenmawia H, Kumarasamy M, Singh SK, Chellappan DK, Gupta G, Prasher P, Dua K, Kumar D. Advances in lung cancer treatment using nanomedicines. ACS Omega. 2022;8(1):10\u201341.","journal-title":"ACS Omega"},{"issue":"5","key":"365_CR15","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s12247-025-10069-6","volume":"20","author":"A Daka Grapci","year":"2025","unstructured":"Daka Grapci A, Breznica Selmani P, Koshi B, Byty\u00e7i I, Koliqi R. Efficacy of drug delivery systems in breast cancer: a meta-analysis of preclinical animal studies. J Pharm Innov. 2025;20(5):168.","journal-title":"J Pharm Innov"},{"issue":"4","key":"365_CR16","doi-asserted-by":"publisher","first-page":"483","DOI":"10.15386\/mpr-1831","volume":"94","author":"R Koliqi","year":"2021","unstructured":"Koliqi R, Breznica P, Daka A, Koshi B. Application of Design of Expert software for evaluating the influence of formulation variables on the encapsulation efficacy, drug content and particle size of PEO-PPO-PEO\/polymeric nanoparticles. Med Pharm Rep. 2021;94(4):483.","journal-title":"Med Pharm Rep"},{"key":"365_CR17","doi-asserted-by":"publisher","first-page":"1211603","DOI":"10.3389\/fonc.2023.1211603","volume":"13","author":"A Jain","year":"2023","unstructured":"Jain A, Bhattacharya S. Recent advances in nanomedicine preparative methods and their therapeutic potential for colorectal cancer: a critical review. Front Oncol. 2023;13:1211603.","journal-title":"Front Oncol"},{"issue":"1","key":"365_CR18","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3390\/cancers12010213","volume":"12","author":"JM Pantshwa","year":"2020","unstructured":"Pantshwa JM, Kondiah PPD, Choonara YE, Marimuthu T, Pillay V. Nanodrug delivery systems for the treatment of ovarian cancer. Cancers (Basel). 2020;12(1):213.","journal-title":"Cancers (Basel)"},{"key":"365_CR19","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"365_CR20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1471-2288-14-43","volume":"14","author":"CR Hooijmans","year":"2014","unstructured":"Hooijmans CR, Rovers MM, de Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE\u2019s risk of bias tool for animal studies. BMC Med Res Methodol. 2014;14:43.","journal-title":"BMC Med Res Methodol"},{"key":"365_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2288-5-13","volume":"5","author":"SP Hozo","year":"2005","unstructured":"Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13.","journal-title":"BMC Med Res Methodol"},{"issue":"11","key":"365_CR22","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358.","journal-title":"Stat Med"},{"key":"365_CR23","doi-asserted-by":"publisher","first-page":"971","DOI":"10.2147\/IJN.S39532","volume":"8","author":"X Gao","year":"2013","unstructured":"Gao X, Wang B, Wei X, Rao W, Ai F, Zhao F, et al. Preparation, characterization and application of star-shaped PCL\/PEG micelles for the delivery of doxorubicin in the treatment of colon cancer. Int J Nanomed. 2013;8:971\u201382.","journal-title":"Int J Nanomed"},{"key":"365_CR24","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.biopha.2018.09.128","volume":"108","author":"S Handali","year":"2018","unstructured":"Handali S, Moghimipour E, Rezaei M, Ramezani Z, Kouchak M, Amini M, et al. A novel 5-fluorouracil targeted delivery to colon cancer using folic acid conjugated liposomes. Biomed Pharmacother. 2018;108:1259\u201373.","journal-title":"Biomed Pharmacother"},{"key":"365_CR25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.lfs.2019.04.030","volume":"227","author":"S Handali","year":"2019","unstructured":"Handali S, Moghimipour E, Kouchak M, Ramezani Z, Amini M, Angali KA, et al. New folate receptor targeted nano liposomes for delivery of 5-fluorouracil to cancer cells: Strong implication for enhanced potency and safety. Life Sci. 2019;227:39\u201350.","journal-title":"Life Sci"},{"issue":"2","key":"365_CR26","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1080\/10837450.2019.1684945","volume":"25","author":"S Handali","year":"2020","unstructured":"Handali S, Moghimipour E, Rezaei M, Ramezani Z, Dorkoosh FA. PHBV\/PLGA nanoparticles for enhanced delivery of 5-fluorouracil as promising treatment of colon cancer. Pharm Dev Technol. 2020;25(2):206\u201318.","journal-title":"Pharm Dev Technol"},{"key":"365_CR27","first-page":"6445","volume":"10","author":"K Liu","year":"2015","unstructured":"Liu K, Wang ZQ, Wang SJ, Liu P, Qin YH, Ma Y, et al. Hyaluronic acid-tagged silica nanoparticles in colon cancer therapy: therapeutic efficacy evaluation. Int J Nanomed. 2015;10:6445\u201354.","journal-title":"Int J Nanomed"},{"issue":"4","key":"365_CR28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s11095-017-2302-4","volume":"35","author":"H Jiang","year":"2018","unstructured":"Jiang H, Shi X, Yu X, He X, An Y, Lu H. Hyaluronidase enzyme-responsive targeted nanoparticles for effective delivery of 5-fluorouracil in colon cancer. Pharm Res. 2018;35(4):73.","journal-title":"Pharm Res"},{"key":"365_CR29","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.ejmech.2014.12.043","volume":"92","author":"VM Le","year":"2015","unstructured":"Le VM, Wang JJ, Yuan M, Nguyen TL, Yin GF, Zheng YH, et al. An investigation of antitumor efficiency of novel sustained and targeted 5-fluorouracil nanoparticles. Eur J Med Chem. 2015;92:882\u20139.","journal-title":"Eur J Med Chem"},{"key":"365_CR30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/1471-2407-8-103","volume":"8","author":"S Li","year":"2008","unstructured":"Li S, Wang A, Jiang W, Guan Z. Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles. BMC Cancer. 2008;8:103.","journal-title":"BMC Cancer"},{"issue":"5","key":"365_CR31","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1158\/1078-0432.CCR-14-1194","volume":"21","author":"B Liang","year":"2015","unstructured":"Liang B, Shahbaz M, Wang Y, Gao H, Fang R, Niu Z, et al. Integrin\u03b26-targeted immunoliposomes mediate tumor-specific drug delivery and enhance therapeutic efficacy in colon carcinoma. Clin Cancer Res. 2015;21(5):1183\u201395.","journal-title":"Clin Cancer Res"},{"issue":"1\u20132","key":"365_CR32","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.ijpharm.2016.09.018","volume":"513","author":"TJ Liang","year":"2016","unstructured":"Liang TJ, Zhou ZM, Cao YQ, Ma MZ, Wang XJ, Jing K. Gemcitabine-based polymer-drug conjugate for enhanced anticancer effect in colon cancer. Int J Pharm. 2016;513(1\u20132):564\u201371.","journal-title":"Int J Pharm"},{"key":"365_CR33","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ejps.2017.12.011","volume":"114","author":"E Moghimipour","year":"2018","unstructured":"Moghimipour E, Rezaei M, Ramezani Z, Kouchak M, Amini M, Angali KA, et al. Folic acid-modified liposomal drug delivery strategy for tumor targeting of 5-fluorouracil. Eur J Pharm Sci. 2018;114:166\u201374.","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"365_CR34","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1208\/s12248-015-9761-5","volume":"17","author":"R Ortiz","year":"2015","unstructured":"Ortiz R, Cabeza L, Arias JL, Melguizo C, \u00c1lvarez PJ, V\u00e9lez C, et al. Poly(butylcyanoacrylate) and Poly(\u03b5-caprolactone) nanoparticles loaded with 5-fluorouracil increase the cytotoxic effect of the drug in experimental colon cancer. AAPS J. 2015;17(4):918\u201329.","journal-title":"AAPS J"},{"key":"365_CR35","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.colsurfb.2017.08.013","volume":"159","author":"G Pan","year":"2017","unstructured":"Pan G, Jia TT, Huang QX, Qiu YY, Xu J, Yin PH, et al. Mesoporous silica nanoparticles (MSNs)-based organic\/inorganic hybrid nanocarriers loading 5-fluorouracil for the treatment of colon cancer with improved anticancer efficacy. Colloids Surf B Biointerfaces. 2017;159:375\u201385.","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"1\u20132","key":"365_CR36","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41434-021-00234-0","volume":"29","author":"S Sanati","year":"2022","unstructured":"Sanati S, Taghavi S, Abnous K, Taghdisi SM, Babaei M, Ramezani M, et al. Fabrication of anionic dextran-coated micelles for aptamer-targeted delivery of camptothecin and survivin-shRNA to colon adenocarcinoma. Gene Ther. 2022;29(1\u20132):55\u201368.","journal-title":"Gene Ther"},{"issue":"4","key":"365_CR37","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1177\/0885328214536940","volume":"29","author":"A Shakeri-Zadeh","year":"2014","unstructured":"Shakeri-Zadeh A, Shiran MB, Khoee S, Sharifi AM, Ghaznavi H, Khoei S. A new magnetic nanocapsule containing 5-fluorouracil: in vivo drug release, anti-tumor, and pro-apoptotic effects on CT26 cells allograft model. J Biomater Appl. 2014;29(4):548\u201356.","journal-title":"J Biomater Appl"},{"issue":"2","key":"365_CR38","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1166\/jbn.2018.2486","volume":"14","author":"L Song","year":"2018","unstructured":"Song L, Zeng A, Hu M, Lin Y, Shu Y, Huang X, et al. Biodegradable polymeric micelle-mediated delivery of a pH-activatable prodrug of 7-ethyl-10-hydroxy-camptothecin (SN-38) to enhance anti-angiogenesis and anti-tumor activity. J Biomed Nanotechnol. 2018;14(2):267\u201380.","journal-title":"J Biomed Nanotechnol"},{"key":"365_CR39","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.2147\/DDDT.S175614","volume":"12","author":"Z Wang","year":"2018","unstructured":"Wang Z, Wei Y, Fang G, Hong D, An L, Jiao T, et al. Colorectal cancer combination therapy using drug and gene co-delivered, targeted poly(ethylene glycol)-\u03b5-poly(caprolactone) nanocarriers. Drug Des Devel Ther. 2018;12:3171\u201380.","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"365_CR40","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1186\/s12885-020-06803-7","volume":"20","author":"P Wu","year":"2020","unstructured":"Wu P, Zhou Q, Zhu H, Zhuang Y, Bao J. Enhanced antitumor efficacy in colon cancer using EGF functionalized PLGA nanoparticles loaded with 5-fluorouracil and perfluorocarbon. BMC Cancer. 2020;20(1):354.","journal-title":"BMC Cancer"},{"key":"365_CR41","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.actbio.2015.04.021","volume":"21","author":"G Xu","year":"2015","unstructured":"Xu G, Shi C, Guo D, Wang L, Ling Y, Han X, et al. Functional-segregated coumarin-containing telodendrimer nanocarriers for efficient delivery of SN-38 for colon cancer treatment. Acta Biomater. 2015;21:85\u201398.","journal-title":"Acta Biomater"},{"key":"365_CR42","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jconrel.2017.07.014","volume":"261","author":"X Yang","year":"2017","unstructured":"Yang X, Xue X, Luo Y, Lin TY, Zhang H, Lac D, et al. Sub-100nm, long tumor retention SN-38-loaded photonic micelles for tri-modal cancer therapy. J Control Release. 2017;261:297\u2013306.","journal-title":"J Control Release"},{"key":"365_CR43","doi-asserted-by":"publisher","first-page":"6737","DOI":"10.2147\/IJN.S267177","volume":"15","author":"Z Yu","year":"2020","unstructured":"Yu Z, Li X, Duan J, Yang XD. Targeted treatment of colon cancer with aptamer-guided albumin nanoparticles loaded with docetaxel. Int J Nanomed. 2020;15:6737\u201348.","journal-title":"Int J Nanomed"},{"issue":"10","key":"365_CR44","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1038\/mt.2016.159","volume":"24","author":"M Zhang","year":"2016","unstructured":"Zhang M, Xiao B, Wang H, Han MK, Zhang Z, Viennois E, et al. Edible ginger-derived nano-lipids loaded with doxorubicin as a novel drug-delivery approach for colon cancer therapy. Mol Ther. 2016;24(10):1783\u201396.","journal-title":"Mol Ther"},{"key":"365_CR45","doi-asserted-by":"publisher","first-page":"20896","DOI":"10.1038\/srep20896","volume":"6","author":"P Zhu","year":"2016","unstructured":"Zhu P, Zhao N, Sheng D, et al. Inhibition of growth and metastasis of colon cancer by delivering 5-fluorouracil-loaded pluronic P85 copolymer micelles. Sci Rep. 2016;6:20896.","journal-title":"Sci Rep"},{"issue":"6","key":"365_CR46","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.3390\/pharmaceutics14061141","volume":"14","author":"R Kandimalla","year":"2022","unstructured":"Kandimalla R, Tomihara H, Banwait JK, Yamamura K, Baba H. Colorectal cancer management: strategies in drug delivery. Pharmaceutics. 2022;14(6):1141.","journal-title":"Pharmaceutics"},{"issue":"7","key":"365_CR47","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3390\/pharmaceutics13071045","volume":"13","author":"TA Al-Hilal","year":"2021","unstructured":"Al-Hilal TA, Alam F, Byun Y. Orally administrable therapeutic nanoparticles for the treatment of colorectal cancer. Pharmaceutics. 2021;13(7):1045.","journal-title":"Pharmaceutics"},{"key":"365_CR48","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.2147\/IJN.S158426","volume":"13","author":"YP Fang","year":"2018","unstructured":"Fang YP, Chuang CH, Wu YJ, Lin HC, Lu YC. SN38-loaded\u2009<\u2009100 nm targeted liposomes for improving poor solubility and minimizing burst release and toxicity: in vitro and in vivo study. Int J Nanomed. 2018;13:2789\u2013802.","journal-title":"Int J Nanomed"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00365-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-026-00365-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00365-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T19:02:59Z","timestamp":1779217379000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43046-026-00365-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["365"],"URL":"https:\/\/doi.org\/10.1186\/s43046-026-00365-8","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"23 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}